GMA-161

DB15397InvestigationalProtein Based Therapies

GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).

Mechanism: Pharmacologically active on Low affinity immunoglobulin gamma Fc region receptor III-B and Low affinity immunoglobulin gamma Fc region receptor III-A
Curator reviewed
Code names: GMA-161

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with GMA-161, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.